Form 6-K Adaptimmune Therapeutics For: Nov 12
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/18/2026
- Wall St set for tepid open as oil prices fall, Treasury yields rise
- Oil prices edge lower on easing fears over Saudi supply disruption
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
Adaptimmune Therapeutics (ADAP) Narrows Q1 Loss
November 13, 2015 8:00 AM ESTAdaptimmune Therapeutics (NASDAQ: ADAP) reported Q1 EPS of $-0.00, versus (GBP0.01) reported last year. Revenue for the quarter came in at GBP2.6 million, versus GBP944 thousand reported last year.
Adaptimmune is reiterating its cash burn guidance. For the six months ending December... More
